PARP inhibitors trang 1 tải miễn phí từ TAILIEUCHUNG

"PARP inhibitors" trang 1 - tải miễn phí từ Tailieuchung

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: A Meta-analysis and systematic review

Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: A Meta-analysis and systematic review

9 44 1

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

11 15 1

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents

13 39 3

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment

10 56 1

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

12 30 1

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

14 11 1

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

13 45 3

Báo cáo y học: " Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP"

14 94 0

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

11 20 1

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors

14 52 1

Design, synthesis, biological evaluation and molecular docking of novel molecules to PARP-1 enzyme

Design, synthesis, biological evaluation and molecular docking of novel molecules to PARP-1 enzyme

26 40 1

Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma

Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma

11 21 3

Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy

Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy

9 7 1

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: A network meta-analysis

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: A network meta-analysis

10 3 1

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

10 19 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.